Digestive Diseases and Sciences

, Volume 59, Issue 1, pp 192–200 | Cite as

Clinical Presentation and Survival of Asian and Non-Asian Patients with HCV-Related Hepatocellular Carcinoma

  • Benjamin Yip
  • James M. Wantuck
  • Lily H. Kim
  • Robert J. Wong
  • Aijaz Ahmed
  • Gabriel Garcia
  • Mindie H. Nguyen
Original Article


Background and Aim

Hepatitis C virus (HCV) is an important cause of hepatocellular carcinoma (HCC) in Asians; however, it is often overlooked due to the high prevalence of hepatitis B virus in Asians. This study examines HCV-related HCC in Asians.


We conducted a retrospective cohort study of 792 consecutive Asian (n = 220) and non-Asian (n = 572) patients with HCV-related HCC identified at Stanford University Medical Center using International Classification of Diseases-9 diagnosis between July 1996 and June 2012.


Asian patients were much older [66 (38–88) vs. 56 (31–87) years, P < 0.0001] and more likely to be female (33 vs. 19 %, P < 0.0001). A larger proportion of Asians were diagnosed with HCC within 2 years of HCV diagnosis (35 vs. 20 %, P = 0.001). Asian patients were more likely to undergo palliative therapy (46 vs. 28 %) and less likely to be listed for liver transplantation (20 vs. 48 %, P < 0.001), despite similar rates of meeting Milan criteria (52 vs. 58 %, P = 0.16). Overall, there was a trend for higher median survival rates in Asians (30 vs. 21 months, P = 0.091). Asians had higher long-term survival with palliative therapy only (5-year survival: 28 vs. 10 %, P < 0.0001); however, survival was similar among patients listed for liver transplantation.


There were distinct differences in clinical presentations of Asian and non-Asian patients with HCV-related HCC. Asians with HCV-related HCC are less likely to undergo liver transplantation and more likely to have delayed HCV diagnosis. Improved strategies in HCV screening in Asians are needed, as it may lead to earlier diagnosis and treatment of HCV infection and possible prevention of HCC development.


Ethnicity Transplant Liver cancer Chronic hepatitis C 



American Association for the Study of Liver Diseases


Barcelona clinic liver cancer


Body mass index




Hepatitis B virus


Hepatocellular carcinoma


Hepatitis C virus


Hazards ratio


International Classification of Diseases-9


Model for end-stage liver disease


Odds ratio


University of California, San Francisco


  1. 1.
    Centers for Disease C, Prevention. Hepatocellular carcinoma—United States, 2001–2006. MMWR Morb Mortal Wkly Rep. 2010;59:517–520.Google Scholar
  2. 2.
    El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–S34.PubMedCrossRefGoogle Scholar
  3. 3.
    Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98:2060–2063.PubMedGoogle Scholar
  4. 4.
    Hwang SJ, Tong MJ, Lai PP, et al. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol. 1996;11:949–954.PubMedGoogle Scholar
  5. 5.
    Ho EY, Ha NB, Ahmed A, et al. Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients. J Viral Hepat. 2012;19:e105–e111.PubMedCrossRefGoogle Scholar
  6. 6.
    Nguyen NH, Vutien P, Trinh HN, et al. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int. 2010;4:523–529.PubMedCrossRefGoogle Scholar
  7. 7.
    Bruix J, Sherman M. Practice guidelines committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.PubMedCrossRefGoogle Scholar
  8. 8.
    Christensen E. Prognostic models including the Child–Pugh, MELD and Mayo risk scores–where are we and where should we go? J Hepatol. 2004;41:344–350.PubMedCrossRefGoogle Scholar
  9. 9.
    Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470.PubMedCrossRefGoogle Scholar
  10. 10.
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.PubMedCrossRefGoogle Scholar
  11. 11.
    Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338.PubMedCrossRefGoogle Scholar
  12. 12.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.PubMedCrossRefGoogle Scholar
  13. 13.
    Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transpl. 2008;8:1982–1989.CrossRefGoogle Scholar
  14. 14.
    Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health. 2011;13:842–848.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(1264):1273. e1261.Google Scholar
  16. 16.
    World Health Organization. Hepatitis C: global prevalence (update). Wkly Epidemiol Rec. 1997;72:341–348.Google Scholar
  17. 17.
    Nguyen LH, Nguyen MH. Systemic review: Asian patients with chronic hepatitis C infecction. Aliment Pharmacol Ther. 2013;37:921–936.PubMedCrossRefGoogle Scholar
  18. 18.
    Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367–1377.PubMedCrossRefGoogle Scholar
  19. 19.
    Siegel AB, McBride RB, El-Serag HB, et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998–2002. Am J Gastroenterol. 2008;103:120–127.PubMedCrossRefGoogle Scholar
  20. 20.
    Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in sureveillance, epidemiology, and end results registries, 1992–2008. Hepatology. 2012;55:476–482.PubMedCrossRefGoogle Scholar
  21. 21.
    Yu JC, Neugut AI, Wang S, et al. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer. 2010;116:1801–1809.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Zak Y, Rhoads KF, Visser BC. Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg. 2011;146:778–784.PubMedCrossRefGoogle Scholar
  23. 23.
    Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502–509. discussion 509–511.PubMedCrossRefGoogle Scholar
  24. 24.
    Singal AG, Chan V, Getachew Y, Guerrero R, Reisch JS, Cuthbert JA. Predictors of liver transplant eligibility for patients with hepatocellular carcinoma in a safety net hospital. Dig Dis Sci. 2012;57:580–586.PubMedCrossRefGoogle Scholar
  25. 25.
    Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32:1407–1414.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci. 2010;55:826–835.PubMedCrossRefGoogle Scholar
  27. 27.
    Ochner M, Wong LL, Wimmer-Kunitomo K. Hepatocellular cancer: risk factors and survival in Pacific Islanders compared to Caucasians in Hawaii. Ethn Dis. 2010;20:169–173.PubMedGoogle Scholar
  28. 28.
    Yang JD, Kim WR, Park KW, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology. 2012;56:614–621.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–716.PubMedCrossRefGoogle Scholar
  30. 30.
    Jun CH, Sim DW, Kim SH. Predictive factors for recurrence and survival in hepatocellular carcinoma in South Korea. Anticancer Res. 2013;33:4129–4134.PubMedGoogle Scholar
  31. 31.
    Nguyen MH, Whittemore AS, Garcia RT, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol. 2004;2:820–824.PubMedCrossRefGoogle Scholar
  32. 32.
    Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.PubMedCrossRefGoogle Scholar
  34. 34.
    Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(120):129. e118.Google Scholar
  35. 35.
    Tong MJ, Chavalitdhamrong D, Lu DS, et al. Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA. J Clin Gastroenterol. 2010;44:e63–e70.PubMedCrossRefGoogle Scholar
  36. 36.
    Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15:323–334. vii–x.PubMedCrossRefGoogle Scholar
  37. 37.
    Profile of General Population and Housing Characteristics: 2010. Demographic Profile Data, 2010. Available at: http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk. Accessed May 16, 2013.

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Benjamin Yip
    • 1
    • 2
  • James M. Wantuck
    • 3
  • Lily H. Kim
    • 4
  • Robert J. Wong
    • 2
  • Aijaz Ahmed
    • 2
  • Gabriel Garcia
    • 2
  • Mindie H. Nguyen
    • 2
  1. 1.Medical SchoolEastern Virginia Medical SchoolNorfolkUSA
  2. 2.Division of Gastroenterology and HepatologyStanford University Medical CenterPalo AltoUSA
  3. 3.Department of MedicineStanford University Medical CenterPalo AltoUSA
  4. 4.Stanford UniversityPalo AltoUSA

Personalised recommendations